Latest News

Katherine Plewes earns Canadian grant for KIMORU based study

Katherine Plewes earns Canadian grant for KIMORU based study

Posted 28/02/2019

Working closely with the University of British Columbia (UBC)'s Support Program to Advance Research Capacity (SPARC), MORU Malaria Researcher Dr Katherine Plewes (right) was recently awarded a 3-year, C$971,551 grant for her study on Evaluating the renoprotective effect of acetaminophen in pediatric severe falciparum malaria: A randomized controlled trial. The study, a much larger version of Katherine’s earlier randomized controlled trial in ...

Guide to sepsis management offers comprehensive, practical advice for resource-limited settings

Guide to sepsis management offers comprehensive, practical advice for resource-limited settings

Posted 26/02/2019

On 12 Feb 2019 a new book, Sepsis Management in Resource-limited Settings, was published. The result of a 3-year project led by MORU and the European Society of Intensive Care Medicine (ESICM), the book was written by critical care physicians from around the globe. Coordinated by honorary MORU member Marcus Schultz, Professor of Intensive Care Medicine in Amsterdam,  with Martin Dünser, an intensivist from Austria, and Arjen Dondorp, Head of ...

DeTACT study begins; will develop two new, safe malaria treatments

DeTACT study begins; will develop two new, safe malaria treatments

Posted 13/02/2019

On 24-25 Jan 2019, investigators met in Bangkok to launch the Developing Triple Artemisinin-based Combination Therapies (DeTACT) Project. Led by MORU and funded by UKaid and the UK Department for International Development (DfID), DeTACT is a large, 14 site trial in 8 African and 5 Asian countries that will study the efficacy, safety and tolerability of two Triple Artemisinin Combination Therapy (TACT) combinations, using combinations of existing ...

Malaria in Cambodia on Sky and PBS News

Malaria in Cambodia on Sky and PBS News

Posted 16/01/2019

Malaria causes nearly half a million deaths worldwide every year. Ninety percent of them are in sub-Saharan Africa, where poor infrastructure limits delivery of drugs. But now there is worry that those drugs are losing effectiveness as disease strains become resistant. In this video, doctors in Northern Cambodia are trialling a new drug combination therapy in a bid to stop the spread of drug resistant strains of malaria.

Sir David Weatherall, 1933-2018

Sir David Weatherall, 1933-2018

Posted 18/12/2018

An inspiring doctor and scientist of great compassion and intellect, Sir David Weatherall died 8 Dec 2018. A Nuffield Professor of Medicine, founder of the MRC Weatherall Institute of Molecular Medicine and a member of Wellcome’s Board throughout the 1990s, Sir David was instrumental in the creation of MORU back in 1979. Here’s what Wellcome and the University of Oxford say about Sir David’s remarkable career.

After MQPH 2018, new collaborations to fight substandard meds

After MQPH 2018, new collaborations to fight substandard meds

Posted 21/11/2018

Over 200 delegates travelled from more than 50 countries to attend the first ever conference on Medicine Quality and Public Health (MQPH 2018) in Oxford from 23-28 Sept. The conference, at Keble College, brought together experts in pharmacy, public health, chemistry, law, sociology, governance and ethics, from medicines regulatory authorities, academia, pharmaceutical industry, NGOs, and international organisations. The many conference partners ...

The Fight Against Malaria Has Reached a Standstill

The Fight Against Malaria Has Reached a Standstill

Posted 20/11/2018

Progress against malaria has stalled, and the disease remains a significant threat to billions of people despite the expensive, decades-long efforts to contain it. In an encouraging development, MORU reported complete success in curing hundreds of patients in Southeast Asia with new three-drug combinations mixing fast-acting artemisinin with two longer-lasting drugs. It it hoped that triple therapy should become the standard for malaria treatment.

Study finds cardiovascular side effects rare with quinoline antimalarials; urges pharmacovigilance

Study finds cardiovascular side effects rare with quinoline antimalarials; urges pharmacovigilance

Posted 09/11/2018

A systematic review analyses the results of 177 trials conducted between 1982 and 2016, including 18,436 patients who underwent electrocardiographic evaluation during malaria clinical trials. Nick White and colleagues found that serious cardiovascular side effects, which include sudden cardiac death, are very rare in the treatment of malaria with quinoline antimalarials. The work emphasises the importance of continued pharmacovigilance with the increasing use of quinoline antimalarials in mass treatment strategies such as intermittent preventative treatment and mass drug administration.

Oxford retains top spot for medicine for eighth consecutive year

Oxford retains top spot for medicine for eighth consecutive year

Posted 09/11/2018

Oxford University has been ranked as the world's best institution for medical and health teaching and research in the Times Higher Education World University Rankings for the eighth consecutive year. This ranking is based on criteria measuring teaching, research, industry income, international outlook and citations. It was noted that both research and clinical trials are supported by our network of international research units in Africa and Asia.

Provide basic health services in villages to eliminate malaria, say researchers in Myanmar

Provide basic health services in villages to eliminate malaria, say researchers in Myanmar

Posted 26/10/2018

Bangkok (Thailand) 25 October 2018 – The incidence of malaria cases continued to drop dramatically in rural and remote Myanmar villages after community workers trained only to detect and treat malaria began providing basic health care as well as malaria services, say University of Oxford affiliated researchers. Adding the health services to malaria control benefitted the villagers access to health and improved malaria services – paving the way ...